Effectiveness of varenicline and counselling for smoking cessation in an observational cohort study in China

Bin Jiang, Yao He, Fang Zuo, Lei Wu, Qing-Hui Liu, Li Zhang, Chang-Xi Zhou, K K Cheng, Sophia S C Chan, Tai Hing Lam, Bin Jiang, Yao He, Fang Zuo, Lei Wu, Qing-Hui Liu, Li Zhang, Chang-Xi Zhou, K K Cheng, Sophia S C Chan, Tai Hing Lam

Abstract

Objectives: To evaluate the effectiveness of varenicline for smoking cessation in Chinese smokers in a real world cessation clinic practice.

Design: A prospective observational study.

Setting: Beijing, China.

Participants: A total of 924 smokers (883 men and 41 women) who attended a smoking cessation clinic of a large general hospital were assessed with data from structured questionnaires at baseline and follow-up at 1, 3 and 6 months. Trained physician counsellors provided free individual counselling for all subjects and follow-up interviews with brief counselling. 332 subjects additionally prescribed varenicline according to their own choice were compared with those without varenicline.

Main outcome measures: Primary outcomes were self-reported 7-day point prevalence abstinence rate and 3-month continuous abstinence rate at 6-month follow-up. Secondary outcomes were 7-day point prevalence abstinence rates at 1 and 3-month follow-up, and 1-month continuous abstinence rate at 3-month follow-up.

Results: By intention-to-treat, the 7-day point prevalence abstinence rate with varenicline and counselling at 6 months was significantly higher than counselling only (37.0% vs 23.1%; OR, 1.75; 95% CI 1.46 to 2.62; p=0.001). The 3-month continuous abstinence rate at 6 months was higher with varenicline (33.1% vs 18.4%; OR, 2.04; 95% CI 1.61 to 2.99; p<0.001). Varenicline also showed better secondary outcomes.

Conclusions: Varenicline prescription in the smoking cessation clinic appeared to be effective with doubling of quit rates in Chinese smokers in a real world cessation clinic practice.

Clinical trial registration: NCT01935505; Results.

Keywords: EPIDEMIOLOGY; PREVENTIVE MEDICINE; PUBLIC HEALTH.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Subject disposition. NRT, nicotine replacement therapy.
Figure 2
Figure 2
Primary outcomes at 6-month follow-up for 7-day point prevalence abstinence rate (7-day PPAR) and 3-month continuous abstinence rate (3-month CAR). CI OR. CAR, continuous abstinence rate; PPAR, point prevalence abstinence rate.

References

    1. Kaleta D, Kozieł A, Miśkiewicz P. MPOWER—strategy for fighting the global tobacco epidemic. Med Pr 2009;60:145–9.
    1. Li Q, Hsia J, Yang GH. Prevalence of smoking in China in 2010. N Engl J Med 2011;364:2469–70. 10.1056/NEJMc1102459
    1. Gonzales D, Rennard SI, Nides M et al. . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47–55. 10.1001/jama.296.1.47
    1. Jorenby DE, Hays JT, Rigotti NA et al. . Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63. 10.1001/jama.296.1.56
    1. Wang C, Xiao D, Chan KP et al. . Varenicline for smoking cessation: A placebo-controlled, randomized study. Respirology 2009;14:384–92. 10.1111/j.1440-1843.2008.01476.x
    1. Tsai ST, Cho HJ, Cheng HS et al. . A randomized, placebo-controlled trial of varenicline, a selective a4b2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin. Ther 2007;29:1027–39. 10.1016/j.clinthera.2007.06.011
    1. Nakamura M, Oshima A, Fujimoto Y et al. . Efficacy and tolerability of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040–56. 10.1016/j.clinthera.2007.06.012
    1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103 10.1002/14651858.CD006103.pub6
    1. Yang G, Ma J, Chen A et al. . Smoking cessation in China: findings from the 1996 national prevalence survey. Tob Control 2001;10:170–4. 10.1136/tc.10.2.170
    1. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29–38. 10.1111/j.1360-0443.2004.00540.x
    1. Wang C, Cho B, Xiao D et al. . Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract 2013;67:469–76. 10.1111/ijcp.12121
    1. Abdullah AS, Hedley AJ, Chan SS et al. , Hong Kong Council on Smoking and Health Smoking Cessation Health Centre (SCHC) Steering Group. Establishment and evaluation of a smoking cessation clinic in Hong Kong: a model for the future service provider. J Public Health (Oxf) 2004;26:239–44. 10.1093/pubmed/fdh147
    1. He Y, Lam TH, Jiang B et al. . Study design and the preliminary results on the modes of smoking cessation in general hospitals. Chin J Epidemiol 2011;32:192–5.
    1. Lam TH, Abdullah AS, Chan SS et al. . Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: a preliminary investigation. Psychopharmacology (Berl) 2005;177:400–8. 10.1007/s00213-004-1971-y
    1. Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J 1990;69:763–5.
    1. Zhu WH, Yang L, Jiang CQ et al. . Characteristics of smokers and predictors of qutting in a smoking cessation clinic in Guangzhou, China. J Public Health (Oxf) 2010;32:267–76. 10.1093/pubmed/fdp107
    1. Prochaska JO, Goldstein MG. Process of smoking cessation. Implications for clinicians. Clin Chest Med 1991;12:727–35.
    1. Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000;45:1200–62.
    1. Liang DH, Liu H, Wei CZ. Clinical observation of varenicline for smoking cessation. Chin J New Clin Med 2011;4:1161–2.
    1. Dhelaria RK, Friderici J, Wu K et al. . Effectiveness of varenicline for smoking cessation at 2 urban academic health centers. Eur J Intern Med 2012;23:461–4. 10.1016/j.ejim.2012.03.017
    1. Blak BT, Wilson K, Metcalfe M et al. . Evaluation of varenicline as an aid to smoking cessation in UK general practice—a THIN database study. Curr Med Res Opin 2010;26:861–70. 10.1185/03007990903526461
    1. Andreas S, Chenot JF, Diebold R et al. . Effectiveness of Varenicline as an Aid to Smoking Cessation in Primary Care: An Observational Study. Eur Addict Res 2013;19:47–54. 10.1159/000341638
    1. Boudrez H, Gratziou C, Messig M et al. . Effectiveness of varenicline as an aid to smoking cessation: Results of an inter-European observational study. Curr Med Res Opin 2011;27: 769–75. 10.1185/03007995.2011.557718
    1. Razavi D, Vandecasteele H, Primo C et al. . Maintaining abstinence from cigarette smoking: effectiveness of group counselling and factors predicting outcome. Eur J Cancer 1999;35:1238–47. 10.1016/S0959-8049(99)00110-0
    1. Hyland A, Li Q, Bauer JE et al. . Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res 2004;6(Suppl 3):S363–9. 10.1080/14622200412331320761
    1. Hymowitz N, Cummings KM, Hyland A et al. . Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control 1997;6(Suppl. 2):S57–62. 10.1136/tc.6.suppl_2.S57
    1. Ebbert JO, Hughes JR, West RJ et al. . Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 2015;313:687–94. 10.1001/jama.2015.280

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit